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Background: Despite the use of modern immunochemotherapy regimens, a significant proportion of diffuse large
B-cell lymphoma (DLBCL) patients will relapse. We proposed absolute lymphocyte count/absolute monocyte count
ratio (ALC/AMC ratio) as a new prognostic factor in relapsed or primary refractory DLBCL.
Methods: We retrospectively analyzed 163 patients who have been diagnosed with relapsed or primary refractory
DLBCL. The overall survival (OS) and progression-free survival (PFS) were measured from the time of first relapse.
The Cox proportional hazards model was used to evaluate ALC/AMC ratio as prognostic factors for OS and PFS.
Results: On univariate and multivariate analysis performed with factors included in the saaIPI, early relapse, prior
exposure to rituximab and autologous stem-cell transplantation (ASCT), the ALC/AMC ratio at the time of first
relapse remained an independent predictor of PFS and OS (PFS: P < 0.001; OS: P < 0.001). Patients with lower
ALC/AMC ratio (<2.0) had lower overall response rate, 1-year PFS and 2-year OS rate compared with those with
higher ALC/AMC ratio (≥2.0). Moreover, the ALC/AMC ratio can provide additional prognostic information when
superimposed on the saaIPI.
Conclusions: Lower ALC/AMC ratio at the time of first relapse is a adverse prognostic factor for OS and PFS in
relapsed or primary refractory DLBCL, and leads to the identification of high-risk patients otherwise classified as
low/intermediate risk by the saaIPI alone.
Keywords: Absolute lymphocyte count/absolute monocyte count ratio, Diffuse large B-cell lymphoma, Relapse,
SaaIPI, SurvivalBackground
Diffuse large B-cell lymphoma (DLBCL) is the most
common, accounts for 25%-30% of all newly diagnosed
cases of adult Non-Hodgkin lymphoma (NHL). It is an
aggressive lymphoma, but is potentially curable [1]. Des-
pite the improvements in overall survival of patients
with DLBCL with the routine addition of rituximab ther-
apy; approximately one-third of the patients will develop
relapsed/refractory disease that remains a major cause of
morbidity and mortality [2]. Salvage chemotherapy* Correspondence: zzzm889@163.com
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unless otherwise stated.followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for
chemosensitive relapsed DLBCL [3]. Various parameters
that greatly affect the results of salvage treatment in pa-
tients who have experienced relapse have been reported.
From the Collaborative Trial in Relapsed Aggressive
Lymphoma (CORAL) study, early relapse less than
12 months after diagnosis, the International Prognostic
Index at relapse (saaIPI) and prior exposure to rituximab
were detected as the parameters that affected 3-year
event-free survival (EFS), progression-free survival (PFS),
and overall survival (OS) [4].
Lymphocytes have an important role in immune sur-
veillance in NHL, a view supported by the observationhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of various subtypes, including DLBCL [5-7]. Monocytes,
which are considered immunologically relevant and are
regarded as a surrogate marker of the tumor microenvir-
onment, were also recently reported to be a prognostic
factor in DLBCL [8-11], follicular lymphoma (FL) [12,13],
T-cell lymphoma [14], extranodal natural killer/T-cell
lymphoma (ENKL) [15] and Hodgkin’s Lymphoma (HL)
[16,17]. Absolute lymphocyte count/absolute monocyte
count ratio (ALC/AMC ratio) at diagnosis, as a simple
biomarker combining an estimate of host immune homeo-
stasis and tumor microenvironment, was recently shown
to be an independent prognostic indicator in HL [16,17]
and DLBCL [10,11]. However, to our best knowledge,
there is no data available on whether the ALC/AMC ratio
at the time of first relapse predicts outcome in patients
with relapsed/primary refractory DLBCL. We, therefore,
assessed the prognostic significance of ALC/AMC ratio at
the time of first relapse.Methods
Ethics statement
This study was approved by the Institutional Review
Board (IRB) of the first affiliated and the second affili-
ated hospital of Anhui medical university. Study was
performed in accord with the principles of the Declar-
ation of Helsinki. All patients agreed to use their medical
records for research.Patients
Consecutive 253 patients with DLBCL who had the full
information, were evaluated and treated with CHOP
(cyclophosphamide, hydroxydaunorubicin, vincristine,
prednisone) or R-CHOP (rituximab-cyclophosphamIde,
hydroxydaunorubicin, vincristine, prednisone) every 3 weeks
for 3 to 8 cycles as first-line therapy and followed up be-
tween the years 2001 and 2011 at the first affiliated hos-
pital and the second hospital of Anhui medical
university, and 163 patients of them who had been diag-
nosed with relapsed/primary refractory. The patients
who achieved CR/uCR/PR after second-line salvage
chemotherapy entered the follow-up or ASCT, and the
patients with no response after second-line salvage
chemotherapy entered the clinical trial or supportive
care. Second-line salvage chemotherapy regimens were:
DHAP/R-DHAP (dexamethasone, cytarabine, and cis-
platin/rituximab, dexamethasone, cytarabine, and cisplatin);
DICE/R-DICE (dexamethasone, ifosfamide, cisplatin, and
etoposide/rituximab, dexamethasone, ifosfamide, cisplatin,
and etoposide); ICE/R-ICE (ifosfamide, carboplatin,
and etoposide/rituximab, ifosfamide, carboplatin, and
etoposide); GDP/R-GDP (gemcitabine, cisplatin, and
dexamethasone/rituximab, gemcitabine, cisplatin, anddexamethasone). HIV-positive patients were excluded
from this study.
Study objective
The absolute lymphocyte count (ALC) and monocyte
count (AMC) at the time of first relapse which were ob-
tained from routine automated complete blood count
(CBC); The absolute monocyte count/absolute lympho-
cyte count ratio (ALC/AMC ratio) was calculated by div-
iding the ALC by the AMC. Response criteria were based
on the criteria from the International Harmonization Pro-
ject [18], and evaluated after the third salvage chemother-
apy course. Complete remission (CR) was defined by the
disappearance of all documented disease; unconfirmed CR
(CRu) was used when a residual mass was present without
evidence of active disease. Partial response (PR) was de-
fined as a 50% reduction of measurable disease. The pri-
mary endpoints were OS and PFS, defined as the time
from the time of first relapse until last follow-up or death,
and as the time from the time of first relapse to disease
progression, relapse, or death of any cause or the last date
of follow-up, respectively. Patient and disease characteris-
tics included in the second-line IPI (sIPI) at the time of re-
lapse or primary refractory disease [age < 60 vs. ≥ 60 years,
Ann Arbor stage (III/IV vs. I/II), Karnofsky performance
status (KPS) (<80% vs. ≥ 80%), lactate dehydrogenase
(LDH) (normal vs. > normal) and number of extra nodal
sites (ENS) involved (≤ vs. > 1)] were utilized.
Statistical analysis
The correlation between the ALC, AMC, ALC/AMC ra-
tio and clinical parameters was assessed by the chi-
square test or Fisher’s exact test. PFS and OS were esti-
mated using the Kaplan-Meier method and two-tailed
log-rank test. Receiver operating characteristics analysis
was also performed to determine the optimal cut-point
for the ALC, AMC and ALC/AMC ratio. The Cox pro-
portional hazards model was used to evaluate the ALC,
AMC and ALC/AMC ratio as prognostic factors for PFS
and OS and to adjust for other known prognostic vari-
ables included in the sIPI. P-values were not adjusted for
multiple comparisons, All two-sided P-values < 0.05 were
determined to be statistically significant. Statistical ana-
lysis was carried out using SPSS 16.0 software.
Results
Patient characteristics
We retrospectively analyzed data from a total of 253
DLBCL patients in this study, median follow-up follow-
ing diagnosis was 36 months for the entire cohort
(range: 3 month to 118 months) and the estimated 5 year
OS for the entire cohort was 56%. Among 163 patients
with evidence of first relapse, 42% had relapsed disease
and 58% had primary refractory disease. The distribution
Table 1 Baseline characteristics based on relapsed/
primary refractory DLBCL patients with an ALC/AMC







Primary reractory 37 57 <0.001
Relapse 53 16
Age (years)
<60 56 49 0.516
≥60 34 24
Gender




80% or more 79 52 0.008
Less than 80% 11 21
Number of extra nodal sites
≤1 74 58 0.654
>1 16 15
Ann Arbor Stage
I/II 44 18 0.002
III/IV 16 55
LDH
≤Normal 65 40 0.021
>Normal 25 33
SaaIPI





CHOP 52 31 0.052
R-CHOP 38 42
Rituximab-containing salvage therapy
No 61 59 0.060
Yes 29 14
ASCT
No 78 67 0.300
Yes 12 6
Salvage therapy





Table 1 Baseline characteristics based on relapsed/
primary refractory DLBCL patients with an ALC/AMC




Abbreviations: ALC/AMC ratio absolute lymphocyte count/absolute monocyte
count ratio, LDH lactate dehydrogenase, saaIPI second-line age-adjusted
International Prognostic Index, CHOP cyclophosphamide, hydroxydaunorubicin,
vincristine, prednisone, R-CHOP rituximab- cyclophosphamIde, hydroxydaunorubicin,
vincristine, prednisone, ASCT autologous stem cell transplantation, DHAP
dexamethasone, cytarabine, and cisplatin, DICE dexamethasone, ifosfamide,
cisplatin, and etoposide, ICE ifosfamide, carboplatin, and etoposide, GDP
gemcitabine, cisplatin, and dexamethasone, R-DHAP rituximab, dexamethasone,
cytarabine, and cisplatin, R-DICE rituximab, dexamethasone, ifosfamide, cisplatin,
and etoposide, R-ICE rituximab, ifosfamide, carboplatin, and etoposide, R-GDP
rituximab, gemcitabine, cisplatin, and dexamethasone.
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fractory patients based on an ALC/AMC ratio ≥ 2.0 ver-
sus ALC/AMC ratio < 2.0 at the time of first relapse is
presented in Table 1. Eleven, Forty-four, sixty-four and
forty-four patients treated with DHAP/R-DHAP, DICE/
R-DICE, ICE/R-ICE, and GDP/R-GDP regimens, re-
spectively, there was no significant difference in charac-
teristic based on ALC/AMC ratio at the time of first
relapse among the different second-line salvage chemo-
therapy (Table 1).
The ALC and AMC at the time of first relapse were
derived from CBC counts. The cutoff points of ALC,
AMC and ALC/AMC ratio for survival outcomes were
selected by the receiver operating characteristic (ROC)
curve analysis. The most discriminative cutoff value of
ALC, AMC and ALC/AMC ratio was 1120/ul (area
under the curve [AUC]: 0.648, 95% confidence interval:
0.563-0.733, P = 0.001), 530/ul (AUC: 0.734, 95% confi-
dence interval: 0.658-0.811, P < 0.001) and 2.0 (AUC:
0.808, 95% confidence interval: 0.741-0.875, P < 0.001),
respectively. In addition, The ALC and AMC at diagno-
sis were derived from pre-treatment CBC counts, and
the cutoff points of ALC (1430/ul), AMC (460/ul) and
ALC/AMC ratio (3.8) for survival outcomes were also
selected by ROC curve analysis [11].
Lower ALC/AMC ratio at the time of first relapse is a
adverse prognostic factor for overall survival and
progression free survival of relapsed/primary refractory
DLBCL patients after second-line therapy
When the components of the sIPI (age ≥ 60 years; KPS <
80%; LDH > normal; Extranodal sites > 1; Ann Arbor
stage III/IV) were assessed in univariate analysis by log
rank, age was not predictive of PFS and OS (PFS: P =
0.531; OS: P = 0.693), whereas Extranodal sites (PFS: P =
0.054; OS: P = 0.029), KPS (P < 0.001 for both), LDH (P <
0.001 for both), and Ann Arbor stage (P < 0.001 for both)
predicted PFS or OS. When entered into a Cox regression
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and Ann Arbor stage remain predictive (Additional file 1:
Table S3 and Additional file 2: Table S4). These significant
components were identical to those in the saaIPI, which
was subsequently used to stratify patients into risk groups.
To determine the prognostic significance of the ALC,
AMC and ALC/AMC ratio at the time of first relapse
for OS and PFS of relapsed/primary refractory DLBCL
patients, on univariate analysis, a relative reduction of
ALC (<1120/ul), elevated AMC (≥530/ul) and lower ALC/
AMC ratio (<2.0) associated with inferior OS (hazard ra-
tio: 3.060, 95% confidence Interval: 1.878-4.988, P < 0.001;
hazard ratio: 3.346, 95% confidence Interval: 2.178-5.141,
P < 0.001; hazard ratio: 9.482, 95% confidence Interval:
5.497-16.355, P < 0.001; respectively). For comparison,
ALC, AMC, ALC/AMC ratio at diagnosis, each of the
three factors that comprise the saaIPI, early relapse
(time from diagnosis to relapse of less than 12 months),
prior rituximab treatment and ASCT or not was in-
cluded in the analysis. Of these, ALC (<1430/ul), AMC
(≥460/ul), ALC/AMC ratio (<3.8) and LDH (>normal)
at diagnosis, LDH (>normal) at the time of first relapse,
KPS (<80%), Ann Arbor stage (stage III/IV), time to re-
lapse after diagnosis, months < 12 and ASCT or not
were also of prognostic significance on univariate ana-
lysis (Table 2).
Then we included components of the saaIPI in a
multivariate analysis with the ALC, AMC, ALC/AMC
ratio at diagnosis and at the time of first relapse, time to
relapse after diagnosis, months < 12 and ASCT or not.
As summarized in Table 2, the ALC/AMC ratio at the
time of first relapse, early relapse (time to relapse afterTable 2 Univariate and multivariate analyses for overall survi
Prognostic factors Univariate analysi
HR (95% CI)
AMC≥ 530/ul 3.346 (2.178-5.141)
ALC < 1120/ul 3.060 (1.878-4.988)
ALC/AMC ratio < 2.0 9.482 (5.497-16.355)
LDH > normal 2.440 (1.603-3.714)
KPS < 80% 2.941 (1.852-4.670)
Ann Arbor stage III/IV 3.088 (1.908-4.997)
ALC/AMC ratio < 3.8 5.626 (3.119-10.174)
AMC≥ 460/ul 2.864 (1.831-4.482)
ALC < 1430/ul 3.017 (1.855-4.907)
LDH (at diagnosis > normal) 3.061 (1.963-4.775)
Time to relapse after diagnosis, months <12 7.003 (4.162-11.783)
Prior rituximab treatment 0.616 (0.592-1.364)
Not ASCT 4.984 (1.819-13.655)
Abbreviations: HR hazard ratio, CI confidence Interval, AMC absolute monocyte coun
absolute monocyte count ratio, LDH lactate dehydrogenase, KPS Karnofsky Performdiagnosis, months < 12) and ASCT or not were inde-
pendently significant prognostic factors for OS, with
hazard ratios of 8.758 (95% confidence Interval: 3.917-
19.581, P < 0.001), 3.527 (95% confidence Interval: 1.597-
7.787, P = 0.002) and 3.877 (95% confidence Interval:
1.310-11.476, P = 0.014), respectively (Table 2). Similarly,
the ALC/AMC ratio at the time of first relapse, early re-
lapse (time to relapse after diagnosis, months < 12) and
ASCT or not were independently significant predictors
of PFS when adjusted for components of the saaIPI on
multivariate analysis (Additional file 3: Table S5).Response and survival rate according to prognostic
factors
After platinum-based second-line salvage chemotherapy,
the overall response rate, including CR, CRu and PR,
was 49%. The factors significantly affecting the overall
response rate included early relapse (time to relapse after
diagnosis, months < 12), saaIPI of 2 to 3, prior rituximab
treatment, ALC/AMC ratio and LDH at the time of first
relapse (P < 0.001) (Table 3). After a median follow-up
time of 13 months, the 1-year PFS rate was 37% and was
significantly different between the ALC/AMC ratio < 2.0
and ALC/AMC ratio ≥ 2.0 (12% and 58%, respectively;
P < 0.001). 2-year OS was 26%, with significant difference
between the ALC/AMC ratio < 2.0 and ALC/AMC ra-
tio ≥ 2.0 (4% and 43%, respectively; P < 0.001). 1-year
PFS and 2-year OS were also affected by early relapse
(time to relapse after diagnosis, months < 12), saaIPI,
rituximab-containing salvage therapy, the ALC, AMC
and LDH at the time of first relapse (Table 3).val
s Multivariate analysis
P HR (95% CI) P
<0.001 1.013 (0.537-1.913) 0.976
<0.001 1.248 (0.704-2.211) 0.448
<0.001 8.758 (3.917-19.581) <0.001
<0.001 1.092 (0.643-1.855) 0.744
<0.001 1.004 (0.592-1.702) 0.989
<0.001 1.061 (0.581-1.937) 0.848
<0.001 1.184 (0.471-2.980) 0.719
<0.001 1.243 (0.696-2.220) 0.462
<0.001 1.387 (0.765-2.513) 0.281
<0.001 1.400 (0.818-2.398) 0.220
<0.001 3.527 (1.597-7.787) 0.002
0.899 - -
0.002 3.877 (1.310-11.476) 0.014
t, ALC absolute lymphocyte count, ALC/AMC ratio absolute lymphocyte count/
ance status, ASCT autologous stem cell transplantation.
Table 3 Response rate and survival according to prognostic factors
Characteristic Response CR/CRu/PR 1-year progression free survival 2-year overall survival
N % P N % P N % P
Time to relapse after diagnosis, months
<12 33 35 <0.001 15 16 <0.001 7 7 <0.001
≥12 47 68 46 67 35 51
Prior rituximab treatment
No 63 67 <0.001 38 40 0.355 20 21 0.126
Yes 17 25 23 33 22 32
SaaIPI at relapse
2–3 16 27 <0.001 10 17 <0.001 5 9 <0.001
0–1 64 67 51 49 37 36
ALC/AMC ratio
<2.0 20 27 <0.001 9 12 <0.001 3 4 <0.001
≥2.0 60 67 52 58 39 43
Absolute monocyte count
≥530/ul 21 33 <0.001 13 20 <0.001 6 9 <0.001
<530/ul 59 60 48 49 36 36
Absolute lymphocyte count
<1120/ul 41 41 0.015 27 27 0.001 15 15 <0.001
≥1120/ul 39 61 34 53 27 42
LDH at relapse
>Normal 16 28 <0.001 12 21 0.001 9 16 0.026
≤Normal 64 61 49 47 33 31
Rituximab containing salvage therapy
No 55 46 0.166 39 33 0.036 22 18 <0.001
Yes 25 58 22 51 20 47
Abbreviations: CR complete remission, CRu unconfirmed complete remission, PR partial response, saaIPI second-line age-adjusted International Prognostic Index,
ALC/AMC ratio absolute lymphocyte count/absolute monocyte count ratio, LDH lactate dehydrogenase.
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second-line therapy
The ALC/AMC ratio at the time of first relapse was ana-
lyzed to determine whether it could further discriminate
for survival when considering second-line therapy with
either ASCT or further chemotherapy. In the 18 first re-
lapsed DLBCL treated with ASCT, the median OS and
PFS were significantly longer for patients with an ALC/
AMC ratio ≥ 2.0 when compared with those patients with
an ALC/AMC ratio < 2.0 (median OS: 34 months, 2 years
OS rates of 92% versus median OS: 19 months, 2 years OS
rates of 17%, P = 0.001; and median PFS: 27 months,1 years
PFS rates of 92% versus median PFS: 15 months, 1 years
PFS rates of 83%, P = 0.596, respectively). In the 145 first
relapsed DLBCL patients that were treated with further
chemotherapy, the median OS and PFS were also signifi-
cantly longer for patients with an ALC/AMC ratio ≥ 2.0
when compared with those patients with an ALC/AMC
ratio < 2.0 (median OS: 18 months, 2 years OS rates of36% versus median OS: 8 months, 2 years OS rates of 3%,
P < 0.001; and median PFS: 12 months, 1 years PFS rates
of 53% versus median PFS: 5 months, 1 years PFS rates of
6%, P < 0.001, respectively).
The ALC/AMC ratio at the time of first relapse identifies
high-risk patients and provides additional prognostic
information when superimposed on the saaIPI
PFS and OS were analyzed using the saaIPI in Figure 1A
and B. The ALC/AMC ratio at the time of first relapse re-
mains an independently significant prognostic factor when
adjusting for the saaIPI. Therefore, we sought to determine
whether it may provide additional prognostic information
when combined with the saaIPI. The 47 low-risk, 100
intermediate-risk (high-intermediate and low-intermediate
were combined) and 16 high-risk patients identified by the
saaIPI were subsequently risk stratified using the ALC/
AMC ratio. We showed that patients with a low-risk cat-
egory of saaIPI score (saaIPI = 0) and low-intermediate/
Figure 1 Kaplan-Meier estimates of overall survival (A) and
progression-free survival (B) for the 163 relapsed/primary
refractory DLBCL patients stratified by second-line age-
adjusted International Prognostic Index (saaIPI) are shown.
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a useful way to distinguish those with favorable outcomes
from those with adverseand outcomes (OS: P = 0.003, PFS:
P = 0.013, Figure 2A and B; OS: P < 0.001, PFS: P < 0.001,
Figure 2C and D; respectively), in conclusion, the ALC/
AMC ratio was able to further risk-stratify these patients.
But in patients with high-risk (saaIPI = 3), the number of
the patients were only sixteen, so as likely not to make a
similar analysis in this subgroup meaningful (OS: P =
0.102, PFS: P = 0.094, Figure 2E and F). In addition, weanalysed 94 primary refractory and 69 relapsed DLBCL pa-
tients to seek to determine whether it may provide add-
itional prognostic information when combined with the
saaIPI, respectively. We showed that in primary refractory
and relapsed patients with a low-intermediate/high-inter-
mediate (saaIPI = 1–2), respectively, the ALC/AMC ra-
tio was a useful way to distinguish those with favorable
outcomes from those with adverse outcomes (OS: P <
0.001, PFS: P < 0.001, Additional file 4: Figure S1C and
D; OS: P < 0.001, PFS: P < 0.001, Additional file 5: Figure
S2C and D; respectively).
Among the all patients, 8% of patients identified by
the saaIPI as ‘low -risk’, upon further risk stratification
by the ALC/AMC ratio (<2.0) at the time of first relapse,
found to have dismal outcomes, with a median OS of
18 months, a median PFS of 10 months; Moreover, 29%
of identified as ‘intermediate -risk’ patients were with a
median OS of 8 months, a median PFS of 6 months.
Similar results were obtained when intermediate risk pa-
tients treated with rituximab-containing salvage therapy
were risk-stratified by the ALC/AMC ratio in Figure 3.
In this case, 26% of identified as ‘intermediate risk’ pa-
tients were with a median OS of 15 months, a median
PFS of 12 months.
Discussion
The International Prognostic Index (IPI), solely consider-
ing patient and tumor characteristics, is currently the
standard prognostic tool used to predict clinical outcomes
for patients with DLBCL. But recent work, based on
gene expression profiling studies in NHL, shows that
gene expression by tumor-infiltrating lymphocytes and
myeloid-derived cells predict a clinical outcome [19],
which implies that a prognostic system that considers
features of the tumor- bearing host and the tumor
microenvironment may provide prognostic information.
The ALC/AMC ratio at diagnosis, as a simple bio-
marker combining an estimate of host immune homeo-
stasis and tumor microenvironment, was recently
shown to be an independent prognostic indicator in HL
[16,17] and DLBCL [10], and combining the dichoto-
mized ALC and AMC to generate the ALC/AMC prog-
nostic score was also provided prognostic information
independently of that included in the IPI [8,9]. There-
fore, we first sought to examine the both in our 253
DLBCL patients from the two hospital institution. In
our study [11], the results were consistent with the pre-
vious findings from Wilcox RA et al., Batty N et al. and
Rambaldi A et al. [8-10].
The international Prognostic Index at relapse (saaIPI),
early relapse less than 12 months after diagnosis and
prior exposure to rituximab have been demonstrated to
be predictors of clinical outcomes in first relapsed
DLBCL patients [4,20]. Biologically, a few parameters at
Figure 2 Kaplan-Meier estimates of overall survival (A, C, E) and progression- free survival (B, D, F) for the 163 relapsed/primary
refractory DLBCL patients stratified by the saaIPI as either low- (A, B), low-intermediate/high-intermediate (C, D) or high risk (E, F)
were further stratified into low or high groups by the ALC/AMC ratio.
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independent of IPI score, including ALC at the time of
first relapse [21]. No reports have addressed whether
ALC/AMC ratio at the time of first relapse predicts sur-
vival in NHL. Thus, we assessed the prognostic signifi-
cance of ALC/AMC ratio at the time of first relapse in
relapsed/primary refractory DLBCL. The present study
showed that ALC/AMC ratio at the time of first relapse
was a adverse independent prognostic factor for OS and
PFS and can identify the high-risk patients otherwise classi-
fied as low/intermediate risk by the saaIPI alone. We also
found that ALC/AMC ratio at the time of first relapse and
several independent factors significantly affected response
rates after salvage therapy, including saaIPI score, early re-
lapse less than 12 months after diagnosis, and prior rituxi-
mab treatment, which is in agreement with those provided
by Gisselbrecht C et al. [4]. ALC/AMC ratio at the time of
first relapse, early relapse less than 12 months after diagno-
sis and saaIPI score, the same independent factors were
found for 1-year PFS and 2-year OS rate. But there were no
difference between the prior rituximab treatment or not;
the fact that most patients in our study who progressedafter R-CHOP have late relapse may explain this discrep-
ancy. In accordance with previous reports [22,23], in our
study, those who received rituximab-containing salvage
therapy at relapse achieved significantly longer survival
(both PFS and OS) and had a significant improvement in
the 1-year PFS and 2-year OS rates than those who under-
went salvage therapy with chemotherapy alone regardless
of the first-line treatment with CHOP or R-CHOP, and
ASCT or not. In addition, among patients who received
first-line treatment with CHOP, those who received
rituximab-containing salvage therapy at relapse achieved
significantly improvement in 2-year OS rate than those
who underwent salvage therapy with chemotherapy alone.
lymphopenia is considered a surrogate marker of host
immunological incompetence, in addition, lymphocytes
(including natural killer [NK] cells) are important media-
tors of antibody-dependent cell-mediated cytotoxicity,
and may be required for rituximab-mediated, antibody-
dependent cellmediated cytotoxicity-dependent destruc-
tion of malignant B cells [24]. Not surprisingly then, lym-
phopenia is an adverse prognostic factor in indolent and
aggressive NHL, including DLBCL. Recently, Dehghani M
Figure 3 Kaplan-Meier estimates of overall survival (A) and
progression-free survival (B) for 43 relapsed/primary refractory
DLBCL patients treated with rituximab-salvage therapy identified
by the saaIPI as intermediate risk (saaIPI =1-2) were further
stratified into low or high groups by the ALC/AMC ratio.
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CD4+ lymphocyte, CD3+ and CD8+ lymphocytes were
corresponding with significantly inferior overall survival
in B-cell NHL, respectively. Głowala-Kosińska M et al.
[27] showed that lower number of circulating regulatory
T cells (Tregs) was associated with reduced chance of
achieving CR and reduced probability of even-free sur-
vival (EFS) in newly diagnosed DLBCL, and Shafer D
et al. [28] showed that low NK cell counts in peripheralblood were associated with inferior overall survival in
patients with FL. However, in the tumor microenviron-
ment, elevated infiltration of FOXP3+ Tregs was corre-
lated with a favorable clinical outcome in different types
of lymphoma reported, including DLBCL [29-33], and
Hasselblom S et al. reported that DLBCL patients with a
small number of cytotoxic T-cell intracytoplasmic antigen-
1 (TIA-1) + T cellshad significantly better outcome [34].
Myeloid-lineage cells, including monocytes and their
progeny, promote tumorigenesis and angiogenesis [35],
and contribute to the suppression of host antitumor im-
munity so that not surprisingly then, development of per-
ipheral blood neutrophilia or monocytosis are adverse
prognostic factors in multiple solid tumors [36-38]. A new
nomenclature defines human monocyte subsets into three,
classical (CD14++CD16-), intermediate (CD14++CD16+)
and nonclassical (CD14 + CD16++) [39]. CD16+ mono-
cytes recently have shown diagnostic and prognostic po-
tential in malignant disease [40-42]. but to date, as far as
we know, are not investigated in lymphoma. Monocytes
that circulate in the bloodstream are recruited to inflamed
tissues and give rise to macrophages. Macrophages, which
termed tumour-associated macrophages (TAMs), play an
important role in tumor tissues. TAMs can be classified
into two functionally distinct types, M1 and M2, which re-
ported to determine the effects against tumors, i.e. promo-
tional (M2) or suppressive (M1) [43]. Hasselblom S et al.
[44] reported that the number of TAMs in DLBCL tissues
was not correlated with the prognosis, but the recent
study of the Osaka Lymphoma Study Group [45] showed
that a high number of M2 TAMs, but not of total TAMs,
was an independent factor for a significantly poor progno-
sis in DLBCL patients.
The pattern of human monocytes recruitment in vivo
to tumors is not very clear, although Qian et al. [46] re-
cently showed that human CD14 + CD16- inflammatory
monocytes recruited by a CCL2 mechanism and differ-
entiate into macrophages that promote the subsequent
growth of metastatic cells in vivo. In addition, Nakasone
ES et al. [47] reported that infiltration of CCR2- express-
ing myeloid cells into chemotherapy-treated tumors con-
tributes to tumor regrowth and relapse after treatment;
recently, Sanford DE et al. [48] found that inflammatory
monocyte (CD14+/CCR2+) recruitment is critical to
pancreatic cancer progression, and targeting CCR2 may
be an effective immunotherapeutic strategy in this dis-
ease. As previously mentioned, We hypothesized that
several important questions could remain: How do the
subsets of blood monocyte exist in DLBCL patients at
the time of first relapse? Do the monocyte subsets vary
when compared with the time of diagnosis? Which
blood monocyte subsets preferentially recruit to meta-
static sites, and involve in tumor microenvironment? Are
there novel specific therapeutic strategies to inhibit the
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and resistance to chemotherapy, so that can increase the
response rate of second-line salvage regimens, prolong the
overall survival? Thus, more further studies are deserved.
In a word, the novel therapy of relapsed DLBCL resulting
from better understanding of patient, tumor characteris-
tics, host immunity and tumor microenvironment may be
needed.
Our study has some limitations. First, although there
was no significant difference in characteristic based on
ALC/AMC ratio at the time of first relapse and response
rate among different second-line salvage chemotherapy
in our study, and no clear superiority of one salvage
regimen over another has been demonstrated all over
the world, this may lower the quality of the data. Thus,
further studies exploring the prognostic significance of
ALC/AMC ratio at the time of first relapse in relapsed/
primary refractory DLBCL patients with uniform salvage
regimens are warranted. Second, on the one hand, as a
retrospective study, patients were not randomly assigned
to ASCT versus other selvage therapies, which meant
that the choice of ASCT or not might have been biased
by the treating physician’s preference based on patient’s
characteristics. Thus, even though ASCT was found to
be a prognostic factor for survival in our study, it is im-
portant to reemphasize the potential bias in patient se-
lectivity undergoing ASCT; on the other hand, the
number of patients who received ASCT was small in our
study, so this should require validation in a larger cohort
in the future. However, our study reported a significantly
superior OS and PFS in patients who underwent ASCT
compared with who received further chemotherapy, which
was in agreement with the result of the 1995 PARMA trial
[49]. The patients with higher ALC/AMC ratio experi-
enced better OS and PFS regardless of their treatment
(ASCT or not), and the ALC/AMC ratio at the time of
first relapse was able to discriminate for survival in both
groups (ASCT and further chemotherapy).
Conclusions
In conclusion, our study identifies prognostic utility for
ALC/AMC ratio at the time of first relapse as a simple
tool in relapsed/primary refractory DLBCL patients. Given
the limited number of patients included in this retrospect-
ive study, the prognostic value will require validation in an
independent cohort of patients in prospective trials, espe-
cially in chemosensitive relapsed DLBCL followed by
high-dose therapy and stem cell transplantation. To our
our knowledge, this study is the first to identify ALC/
AMC ratio the prognostic significance independent of the
saaIPI to predict response rate and survival outcome in re-
lapsed/refractory DLBCL patients and add to its ability to
identify high-risk patients. As new immuno-based therap-
ies are developed to treat relapsed NHL, the role of thehost immune homeostasis and tumor microenvironment,
such as targeting monocyte mobilization, is becoming
more important in these treatment modalities.
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